Exopharm has focused on R&D along with key appointments during the start of the new financial year to support its ambitious goal of becoming a leading global exosome medicine company.
Shares in exosome medicine company Exopharm (ASX: EX1) peaked almost 12% today after a positive Q1FY22 trading update, with the company making significant advances in R&D and key appointments to drive future growth.
Exopharm has taken several crucial steps forward in Q1 with its LEAP – Ligand-based Exosome Affinity Purification – technology. LEAP is showing promise in reducing a major obstacle in the advancement of exosomes as a new form of medicine for a range of diseases including degenerative diseases and cancer.
An inability to easily purify a large scale of exosomes from source material, which can include blood or cell media grown in a laboratory, had been holding back the sector.
LEAP uses a chromatography-based purification process to reduce the bottleneck and is the only technology available to provide large quantities of high-purity exosomes.
The company has kicked off the FY22 financial year with business development activities and building momentum around LEAP.